2.051
前日終値:
$2.07
開ける:
$2.07
24時間の取引高:
289.31K
Relative Volume:
0.05
時価総額:
$7.26M
収益:
-
当期純損益:
$-23.42M
株価収益率:
-0.0263
EPS:
-78
ネットキャッシュフロー:
$-16.67M
1週間 パフォーマンス:
-14.61%
1か月 パフォーマンス:
+94.36%
6か月 パフォーマンス:
-51.06%
1年 パフォーマンス:
-87.29%
Mustang Bio Inc Stock (MBIO) Company Profile
MBIO を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
MBIO
Mustang Bio Inc
|
2.055 | 10.59M | 0 | -23.42M | -16.67M | -78.00 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
469.80 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
559.63 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.77 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
573.25 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.76 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Mustang Bio Inc Stock (MBIO) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2021-05-18 | 開始されました | BTIG Research | Buy |
2020-10-02 | 開始されました | B. Riley FBR | Buy |
2019-11-20 | 開始されました | Cantor Fitzgerald | Overweight |
2019-08-13 | 開始されました | H.C. Wainwright | Buy |
2019-06-21 | 開始されました | Cantor Fitzgerald | Overweight |
2017-12-21 | 開始されました | Oppenheimer | Outperform |
すべてを表示
Mustang Bio Inc (MBIO) 最新ニュース
What analysts say about Mustang Bio Inc. stockUnprecedented profits - jammulinksnews.com
What drives Mustang Bio Inc. stock priceExtraordinary profit generation - jammulinksnews.com
Mustang Bio Inc. Stock Analysis and ForecastPhenomenal investment performance - Autocar Professional
Is Mustang Bio Inc. a good long term investmentBreakthrough wealth creation - jammulinksnews.com
Mustang Bio (NASDAQ:MBIO) Upgraded to “Hold” at Wall Street Zen - Defense World
How Mustang Bio Inc. stock performs during market volatility200 Percent Gain Alert - Newser
Why Mustang Bio Inc. stock attracts strong analyst attentionSafe Entry High Exit Alerts - Newser
What makes Mustang Bio Inc. stock price move sharplyTriple Digit Return Forecasts - Newser
MBIO Stock: Exploring Mustang Bio Inc’s Growth - investchronicle.com
Mustang Bio Shares Skyrocket After Orphan Drug Designation - StocksToTrade
Mustang Bio’s Shares Skyrocket as FDA Grants Orphan Drug Designation - timothysykes.com
Promising Small Cap Stocks Worth Watching – July 7th - Defense World
Top Penny Stocks To Follow Now – July 7th - Defense World
Mustang Bio’s Meteoric Surge: What’s Driving Up MBIO? - StocksToTrade
Mustang Bio’s Stock Soars: What’s Driving the Surge? - timothysykes.com
Mustang Bio Receives FDA Orphan Drug Designation - TipRanks
Best Medical Stocks To Follow Today – July 7th - Defense World
Promising Pharmaceutical Stocks To Consider – July 7th - Defense World
Top Biotech Stocks To Research – July 7th - Defense World
Calidi Biotherapeutics Stock Jumps 39% After Hours — What's Going On - Benzinga
Mustang Bio Ignites Bullish Retail Buzz As FDA Grants Orphan Status To Brain Cancer Drug - NewsBreak: Local News & Alerts
MBIO Soars on Orphan Drug Nod for Investigational Brain Cancer Therapy - TradingView
Mustang Bio Stock Jumps 180% After FDA Grants Orphan Drug Status to Brain Cancer Drug - inkl
Why Did Mustang Bio Plunge 11.68% After 196.21% Surge? - AInvest
Market Wrap | US Stocks Slide as Fed Rate Cut Hints Emerge Palantir and Mustang Bio Soar - AInvest
Mustang Bio (MBIO) Stock Explodes 260% After FDA Grants Key Cancer Drug Designation - Benzinga
Dow Dips 1%; Mustang Bio Shares Spike Higher - inkl
Biotech Stock Analysis: MBIO Soars after FDA Grants Orphan Drug Designation - Markets.com
This BlackRock stock just spiked over 300% - Finbold
Mustang Bio Stock Surges: Time to Reconsider? - StocksToTrade
FDA grants orphan drug status to Mustang Bio’s glioma treatment By Investing.com - Investing.com Canada
Mustang Bio’s Drastic Turn: Opportunity or Red Flag? - timothysykes.com
Mustang Bio rises after FDA orphan drug status for MB-101 - Seeking Alpha
Mustang Bio stock soars after FDA grants orphan drug designation By Investing.com - Investing.com South Africa
Mustang Bio stock soars after FDA grants orphan drug designation - Investing.com
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma - The Manila Times
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for - GlobeNewswire
Breakthrough Brain Cancer Treatment: FDA Backs Mustang Bio Therapy After 66-Month Complete Response in Trials - Stock Titan
Mustang Bio Plunges 25.37% Amid Reverse Split, Financial Woes - AInvest
Mustang Bio (NASDAQ:MBIO) Shares Down 5.1% – What’s Next? - Defense World
ASCO: Kite’s Glioblastoma CAR-T Highlights Solid Tumor Progress - insights.citeline.com
Mustang Bio Inc (MBIO) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):